Harrow, Inc. (HROW)
50.52
+0.32
(+0.64%)
USD |
NASDAQ |
Dec 11, 15:43
Harrow EPS Diluted (Quarterly): 0.0262 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -0.3495 |
| Skye Bioscience, Inc. | -0.3216 |
| Theravance Biopharma, Inc. | 0.0696 |
| FibroGen, Inc. | 36.71 |
| Myomo, Inc. | -0.0869 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.02M |
| Revenue (Quarterly) | 71.64M |
| Total Expenses (Quarterly) | 70.62M |
| Enterprise Value | 2.037B |
| Gross Profit Margin (Quarterly) | 75.28% |
| Profit Margin (Quarterly) | 1.42% |
| Earnings Yield | -0.30% |
| Operating Earnings Yield | 1.49% |
| Normalized Earnings Yield | -0.0152 |